Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Equillium, Inc. - Common Stock
(NQ:
EQ
)
2.260
+0.050 (+2.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Equillium, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
April 25, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
April 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
March 23, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium's Itolizumab Shows Durable Clinical Response In GvHD Patients
↗
March 23, 2022
Equillium Inc (NASDAQ: EQ) announced two oral presentations on itolizumab at the Annual Meeting of the European Society for Blood and Marrow Transplantation.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
↗
March 17, 2022
Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to...
Via
Benzinga
Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition
↗
February 16, 2022
Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. The deal,...
Via
Benzinga
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
February 16, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Provides Timing Update on Conference Presentations
February 15, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
February 09, 2022
From
Equillium, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
January 21, 2022
Gainers Mustang Bio (NASDAQ:MBIO) shares ...
Via
Benzinga
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
January 10, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
January 05, 2022
From
Equillium, Inc.
Via
Business Wire
10 Biggest Price Target Changes For Wednesday
↗
January 05, 2022
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...
Via
Benzinga
45 Biggest Movers From Yesterday
↗
January 05, 2022
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced...
Via
Benzinga
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium To Reassess Potential For Its Asthma Trials
↗
January 04, 2022
Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target...
Via
Benzinga
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
January 04, 2022
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
December 13, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
November 10, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at Two Upcoming Investor Conferences
November 09, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
November 05, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
November 05, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
November 04, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients
↗
November 02, 2021
Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were...
Via
Benzinga
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
November 02, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
October 18, 2021
From
Equillium, Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
September 30, 2021
From
Equillium, Inc.
Via
Business Wire
Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021
From
Equillium, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
